Probiodrug

Probiodrug is a biopharmaceutical company dedicated to the research and development of novel therapeutic solutions to treat people with Alzheimer’s Disease.

Probiodrug floated on Euronext Amsterdam with an initial market capitalisation of €102m
Proceeds of the offering will be used to execute the phase 2a study of its lead product in Alzheimer’s patients
Efforts resulted in an order book mainly made up of long-term specialist investors, despite turbulent markets